{"id": "1363210190452064259", "creation": 1613849611.0, "user_id": "1233901069366771712", "social_network": "twitter", "nsfw": false, "request": ["b26b9dbc-1c5a-4cd3-a3a6-c2f5a51ad0fc"], "metrics": {"b26b9dbc-1c5a-4cd3-a3a6-c2f5a51ad0fc": {"retweet_count": 0, "reply_count": 0, "like_count": 1, "quote_count": 0}}, "text": "Can COVID-19 Vaccine Developer, Novavax, Stock Hit $400 a Share?\n\n.@Novavax\u2019 stead is the fact that against the latest #VariantsOfConcern, its #Covid19 #vaccine, is the only candidate with \u201crobust volume\u201d of clinical data\n\n$NVAX $MRNA $JNJ $INO #ALT\n\nhttps://t.co/jiH53HONfk", "first_save": 1634559108.199414, "hashtags": ["#VARIANTSOFCONCERN", "#COVID19", "#VACCINE", "#ALT"]}